company background image
RVTY logo

Revvity Informe acción NYSE:RVTY

Último precio

US$102.09

Capitalización de mercado

US$12.6b

7D

2.7%

1Y

-20.6%

Actualizada

25 Apr, 2024

Datos

Finanzas de la empresa +

Revvity, Inc.

Informe acción NYSE:RVTY

Capitalización de mercado: US$12.6b

Competidores de Revvity, Inc.

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Revvity
Historical stock prices
Current Share PriceUS$102.09
52 Week HighUS$132.54
52 Week LowUS$79.50
Beta1.09
1 Month Change-1.29%
3 Month Change-7.19%
1 Year Change-20.59%
3 Year Change-21.77%
5 Year Change7.60%
Change since IPO2,981.96%

Noticias y actualizaciones recientes

Why We're Not Concerned About Revvity, Inc.'s (NYSE:RVTY) Share Price

Apr 03
Why We're Not Concerned About Revvity, Inc.'s (NYSE:RVTY) Share Price

Revvity: Enter Now As Reorganization Takes Shape

Mar 21

Recent updates

Why We're Not Concerned About Revvity, Inc.'s (NYSE:RVTY) Share Price

Apr 03
Why We're Not Concerned About Revvity, Inc.'s (NYSE:RVTY) Share Price

Revvity: Enter Now As Reorganization Takes Shape

Mar 21

We Think Revvity (NYSE:RVTY) Can Stay On Top Of Its Debt

Feb 28
We Think Revvity (NYSE:RVTY) Can Stay On Top Of Its Debt

Investors Can Find Comfort In Revvity's (NYSE:RVTY) Earnings Quality

Feb 13
Investors Can Find Comfort In Revvity's (NYSE:RVTY) Earnings Quality

Should You Think About Buying Revvity, Inc. (NYSE:RVTY) Now?

Jan 19
Should You Think About Buying Revvity, Inc. (NYSE:RVTY) Now?

An Intrinsic Calculation For Revvity, Inc. (NYSE:RVTY) Suggests It's 49% Undervalued

Jan 04
An Intrinsic Calculation For Revvity, Inc. (NYSE:RVTY) Suggests It's 49% Undervalued

Revvity: More Than A Name Change Is Needed For PerkinElmer

Dec 29

Why We're Not Concerned About Revvity, Inc.'s (NYSE:RVTY) Share Price

Dec 20
Why We're Not Concerned About Revvity, Inc.'s (NYSE:RVTY) Share Price

Is Revvity (NYSE:RVTY) Using Too Much Debt?

Oct 07
Is Revvity (NYSE:RVTY) Using Too Much Debt?

Revvity: Recent Investments, Acquisitions, Not Pulling Economic Weight (Rating Downgrade)

Oct 04

At US$108, Is Revvity, Inc. (NYSE:RVTY) Worth Looking At Closely?

Sep 22
At US$108, Is Revvity, Inc. (NYSE:RVTY) Worth Looking At Closely?

An Intrinsic Calculation For Revvity, Inc. (NYSE:RVTY) Suggests It's 40% Undervalued

Aug 17
An Intrinsic Calculation For Revvity, Inc. (NYSE:RVTY) Suggests It's 40% Undervalued

Revvity: New Name - But New Investment Outlook? Reiterate Buy

Jul 18

Revvity (NYSE:RVTY) Seems To Use Debt Quite Sensibly

Jul 03
Revvity (NYSE:RVTY) Seems To Use Debt Quite Sensibly

What Does Revvity, Inc.'s (NYSE:RVTY) Share Price Indicate?

Jun 17
What Does Revvity, Inc.'s (NYSE:RVTY) Share Price Indicate?

Calculating The Fair Value Of Revvity, Inc. (NYSE:PKI)

May 16
Calculating The Fair Value Of Revvity, Inc. (NYSE:PKI)

We Think PerkinElmer (NYSE:PKI) Can Stay On Top Of Its Debt

Mar 28
We Think PerkinElmer (NYSE:PKI) Can Stay On Top Of Its Debt

When Should You Buy PerkinElmer, Inc. (NYSE:PKI)?

Mar 13
When Should You Buy PerkinElmer, Inc. (NYSE:PKI)?

PerkinElmer Q4 2022 Earnings Preview

Feb 13

A Look At The Intrinsic Value Of PerkinElmer, Inc. (NYSE:PKI)

Feb 10
A Look At The Intrinsic Value Of PerkinElmer, Inc. (NYSE:PKI)

PerkinElmer: Capital Budgeting A Key Factor To The Investment Debate

Jan 31

Danaher earnings weigh on other life sciences tools, services companies

Jan 24

PerkinElmer says Q4 results will meet or exceed prior guidance

Jan 09

PerkinElmer (NYSE:PKI) Has A Pretty Healthy Balance Sheet

Dec 27
PerkinElmer (NYSE:PKI) Has A Pretty Healthy Balance Sheet

Is It Time To Consider Buying PerkinElmer, Inc. (NYSE:PKI)?

Dec 12
Is It Time To Consider Buying PerkinElmer, Inc. (NYSE:PKI)?

PerkinElmer receives FDA approval for EONIS assay for spinal muscular atrophy in newborns

Nov 14

PerkinElmer reports mixed Q3 earnings, initiates Q4 and updates FY22 pro forma guidance

Nov 08

PerkinElmer, Inc.'s (NYSE:PKI) Intrinsic Value Is Potentially 48% Above Its Share Price

Oct 28
PerkinElmer, Inc.'s (NYSE:PKI) Intrinsic Value Is Potentially 48% Above Its Share Price

PerkinElmer declares $0.07 dividend

Oct 27

PerkinElmer expects Q3 earnings to exceed prior outlook

Oct 17

Rentabilidad de los accionistas

RVTYUS Life SciencesMercado US
7D2.7%3.6%1.0%
1Y-20.6%3.2%21.9%

Rentabilidad vs. Industria: RVTY obtuvo unos resultados inferiores a los del sector US Life Sciences , que el año pasado arrojó un rendimiento del 4.7%.

Rentabilidad vs. Mercado: RVTY obtuvo unos resultados inferiores a los del mercado US, que fue del 24.9% el año pasado.

Volatilidad de los precios

Is RVTY's price volatile compared to industry and market?
RVTY volatility
RVTY Average Weekly Movement3.8%
Life Sciences Industry Average Movement6.9%
Market Average Movement6.0%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Precio estable de las acciones: RVTY no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de RVTY (4%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

FundadaEmpleadosCEOPágina web
193711,500Prahlad Singhwww.revvity.com

Revvity, Inc. ofrece soluciones, tecnologías y servicios de ciencias de la salud en América, Europa y Asia, así como a escala internacional. El segmento de ciencias de la vida proporciona instrumentos, reactivos, informática, software, suscripciones, detección, tecnologías de imagen, garantías, formación y servicios. Su segmento Diagnostics suministra instrumentos, reactivos, plataformas de ensayo y productos de software para la detección precoz de trastornos genéticos, como el embarazo y la primera infancia, así como pruebas de enfermedades infecciosas en el mercado del diagnóstico.

Resumen de fundamentos de Revvity, Inc.

¿Cómo se comparan los beneficios e ingresos de Revvity con su capitalización de mercado?
Estadísticas fundamentales de RVTY
Capitalización bursátilUS$12.61b
Beneficios(TTM)US$179.50m
Ingresos (TTM)US$2.75b

70.3x

Ratio precio-beneficio (PE)

4.6x

Ratio precio-ventas (PS)

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de RVTY
IngresosUS$2.75b
Coste de los ingresosUS$1.21b
Beneficio brutoUS$1.54b
Otros gastosUS$1.36b
BeneficiosUS$179.50m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

Apr 29, 2024

Beneficios por acción (BPA)1.45
Margen bruto55.98%
Margen de beneficio neto6.53%
Ratio deuda/patrimonio49.5%

¿Cómo se ha desempeñado RVTY a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

0.3%

Rentabilidad actual por dividendo

19%

Ratio de pagos